{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:36:01Z","timestamp":1773106561810,"version":"3.50.1"},"reference-count":13,"publisher":"Scientific Foundation Spiroski (publications)","issue":"1","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Open Access Maced J Med Sci"],"abstract":"<jats:p>BACKGROUND: Melanoma appears to be a malignant disease, whose development can be potentiated by different drug groups. More and more data are in favour of the claim that commonly used antihypertensive drugs also contain the risk of developing melanoma. The most evidence is that angiotensin receptor blockers may be carcinogenic. Two representatives from this group, valsartan and irbesartan, produced by certain pharmaceutical companies are being withdrawn from the market due to finding content of NDMA and NDEA, which are believed to be potent carcinogens. Another representative of this group, losartan, according to in vitro data, potentiates cell adhesion and invasion of human melanoma cells.\r\nCASE REPORT: We present a 45-year-old man with arterial hypertension. For year and a half\/two years, the patient is on systemic therapy with Aspirin and Irbesartan\/Hydrochlorothiazide. The patient also reported about the presence of a pigmented lesion in the abdominal area, which occurred 5-6 years ago, before the onset of cardiac therapy. According to him, there was a change in the colour and size of the lesion within the framework of cardiac therapy (from 1.5-2 years). Innovative one step melanoma surgery was performed, and the lesion was radically removed with a 1 cm operational safety margin in all directions within one operative session. The subsequent histological verification found the presence of thin melanoma.\r\nCONCLUSION: Drug-induced melanoma turned out to be a problem of significant importance. The group of angiotensin receptor blockers should be investigated more thoroughly and in detail on the probability of potentiating carcinogenesis. We describe an interesting case showing the progression of pigment lesion to melanoma as a possible result of irbesartan therapy, i.e. we share a theory that differs from that of drug-induced de novo melanomas. It should not be overlooked the fact that another widely used drug-Aspirin, is also likely to potentiate the development of melanoma. Furthermore, the case is indicative of the use of one step melanoma surgery in a melanoma patient with a thickness less than 1 mm.<\/jats:p>","DOI":"10.3889\/oamjms.2019.042","type":"journal-article","created":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T14:53:21Z","timestamp":1547304801000},"page":"114-116","source":"Crossref","is-referenced-by-count":6,"title":["Drug-Induced Melanoma: Irbesartan Induced Cutaneous Melanoma! First Description in the World Literature!"],"prefix":"10.3889","volume":"7","author":[{"given":"Georgi","family":"Tchernev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivanka","family":"Temelkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"52292","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"key":"61339","doi-asserted-by":"crossref","unstructured":"Tang H, Zhai S, Song Y, Han J. Use of Antihypertensive Drugs and Risk of Malignant Melanoma: A Meta-analysis of Observational Studies. Drug Saf. 2018; 41(2):161-169. https:\/\/doi.org\/10.1007\/s40264-017-0599-x PMid:28905299","DOI":"10.1007\/s40264-017-0599-x"},{"key":"61340","doi-asserted-by":"crossref","unstructured":"Nardone B, Orrell K, Vakharia P, West D. Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-\u00ce\u00b1Is), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence. Expert Opin Drug Saf. 2018; 17(2):139-147. https:\/\/doi.org\/10.1080\/14740338.2018.1400530 PMid:29103328","DOI":"10.1080\/14740338.2018.1400530"},{"key":"61341","doi-asserted-by":"crossref","unstructured":"Olschewski D, Hofschr\u00c3\u00b6er V, Nielsen N, Seidler D, Schwab A, Stock C. The Angiotensin II Type 1 Receptor Antagonist Losartan Affects NHE1-Dependent Melanoma Cell Behavior. Cell Physiol Biochem. 2018; 45:2560-2576. https:\/\/doi.org\/10.1159\/000488274 PMid:29558744","DOI":"10.1159\/000488274"},{"key":"61342","doi-asserted-by":"crossref","unstructured":"Sipahi I, Debanne S, Rowland D, Simon D, Fang J. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11(7):627-36. https:\/\/doi.org\/10.1016\/S1470-2045(10)70106-6","DOI":"10.1016\/S1470-2045(10)70106-6"},{"key":"61343","doi-asserted-by":"crossref","unstructured":"Schmidt S, Schmidt M, Mehnert F, Lemeshow S, S\u00c3\u00b8rensen H. Use of antihypertensive drugs and risk of skin cancer. J Eur Acad Dermatol Venereol. 2015; 29(8):1545-54. https:\/\/doi.org\/10.1111\/jdv.12921 PMid:25640031","DOI":"10.1111\/jdv.12921"},{"key":"61344","unstructured":"D'Arrigo T. FDA issues statement as valsartan recalls grow. AphA, September 4, 2018. Retrieved from https:\/\/www.pharmacist.com\/article\/fda-issues-statement-valsartan-recalls-grow"},{"key":"61345","unstructured":"Christensen J. FDA expands recall of blood pressure drug valsartan due to cancer concern. CNN, August 10, 2018. Retrieved from https:\/\/edition.cnn.com\/2018\/08\/08\/health\/valsartan-recall-fda-expanded\/index.html"},{"key":"61346","unstructured":"WJZ, CBS Baltimore. FDA Recalls Common Blood Pressure Medicine Due To Cancer Concerns. July 17, 2018."},{"key":"61347","unstructured":"Wendling P. More Drug Makers Tagged as Valsartan Recall Grows. WebMD, August 13, 2018. Retrieved from https:\/\/www.webmd.com\/heart-disease\/news\/20180813\/more-drug-makers-tagged-as-valsartan-recall-grows"},{"key":"61348","unstructured":"Howard J. Valsartan recall: 4 things patients should know. CNN, August 28, 2018. Retrieved from https:\/\/edition.cnn.com\/2018\/07\/19\/health\/valsartan-recall-explainer\/index.html"},{"key":"61349","unstructured":"Herman A. Another Potential Carcinogen Found in Valsartan. NEJM Journal Watch, September 17, 2018. Retrieved from https:\/\/www.jwatch.org\/fw114583\/2018\/09\/17\/another-potential-carcinogen-found-valsartan"},{"key":"61350","unstructured":"Brooks M. FDA Issues Alert on Irbesartan Due to Contamination. Medscape Medical News, November 01, 2018. Retrieved from https:\/\/www.medscape.com\/viewarticle\/904270"},{"key":"61351","doi-asserted-by":"crossref","unstructured":"Liu L, Fan X, Li H, An X, Yang R. Angiotensin II promotes melanogenesis via angiotensin II type 1 receptors in human melanocytes. Mol Med Rep. 2015; 12(1):651-6. https:\/\/doi.org\/10.3892\/mmr.2015.3438 PMid:25760379","DOI":"10.3892\/mmr.2015.3438"}],"container-title":["Open Access Macedonian Journal of Medical Sciences"],"original-title":[],"link":[{"URL":"https:\/\/oamjms.eu\/index.php\/mjms\/article\/download\/oamjms.2019.042\/2742","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/oamjms.eu\/index.php\/mjms\/article\/download\/oamjms.2019.042\/2788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T11:01:05Z","timestamp":1692529265000},"score":1,"resource":{"primary":{"URL":"https:\/\/oamjms.eu\/index.php\/mjms\/article\/view\/oamjms.2019.042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,15]]}},"URL":"https:\/\/doi.org\/10.3889\/oamjms.2019.042","relation":{},"ISSN":["1857-9655"],"issn-type":[{"value":"1857-9655","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]}}}